Tonix Pharmaceuticals Presents Promising Preclinical Immuno-Oncology Data at AACR 2026

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced new preclinical data from its immuno-oncology portfolio, including TNX-1700 and TNX-4700, presented through one oral and two poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The findings support the potential of these candidates in cancer treatment, particularly in gastric cancer and as a checkpoint inhibitor combination therapy.

The data on TNX-1700, a modified version of the enzyme prolyl oligopeptidase (PREP), demonstrated its ability to reduce inflammation and tumor progression in preclinical models of gastric cancer. PREP is known to play a role in the degradation of collagen and other extracellular matrix components, and its inhibition has been linked to anti-inflammatory and anti-fibrotic effects. Tonix reported that TNX-1700 showed favorable pharmacokinetics, suggesting it could be a viable therapeutic option for gastric cancer, a disease with high unmet medical need.

TNX-4700, a monoclonal antibody targeting BTLA (B- and T-lymphocyte attenuator), showed promising in vitro activity. BTLA is an immune checkpoint receptor that inhibits T-cell activation, and its blockade can enhance anti-tumor immune responses. Tonix highlighted that TNX-4700 has potential as a cancer immunotherapy candidate, either alone or in combination with other checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4 antibodies. This approach could broaden the therapeutic landscape for patients who do not respond to existing immunotherapies.

The presentations at AACR 2026 underscore Tonix's commitment to advancing its immuno-oncology pipeline. The company is known for its focus on central nervous system (CNS) and immunology treatments, with its recently approved flagship medicine TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia. Tonix's CNS portfolio also includes products for acute migraine, such as Zembrace SymTouch and Tosymra, and ongoing Phase 2 trials for TONMYA in major depressive disorder and acute stress disorder. Additionally, the company is developing TNX-2900 for Prader-Willi syndrome and advancing immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a CD40 ligand inhibitor for kidney transplant rejection.

The preclinical data for TNX-1700 and TNX-4700 are significant as they address key challenges in cancer treatment: inflammation-driven tumor progression and immune evasion. If these findings translate to clinical success, Tonix could offer new options for patients with gastric cancer and other malignancies. The company plans to further evaluate these candidates in clinical trials, with more details expected in future announcements.

For more information, visit the company's newsroom at https://ibn.fm/TNXP.